Study on tigecycline in the treatment of pneumonia patients with carbapenems-resistant acinetobacter baumannii

Abstract

Objective To evaluate the effect and safety of high-dose of tigecycline in the treatment of pneumonia caused by carbapenems-resistant acinetobacter baumannii. Methods The clinical data of 46 patients with pneumonia caused by carbapenems-resistant acinetobacter baumannii were retrospectively analyzed in the Department of Respiratory Medicine and RICU of Affiliated Zhengzhou Central Hospital of Zhengzhou University from February 2016 to August 2017. All patients were treated with tigecycline, and the patients were divided into routine-dose group (24 cases) and high-dose group (22 cases). The patients in routine-dose group were given routine-dose of tigecycline (initial dose of 100 mg, and then 50 mg each time, q12 h); the patients in high-dose group were given high-dose of tigecycline (100 mg each time, q12 h); both of the two groups were combined with cefbperazone-sulbactam (1 g each time, q8 h by sulbatam). The clinical efficacy, rates of bacterial clearance, incidences of adverse drug reaction and hospitalization days were compared between the two groups. Results After treatment, the rate of clinical efficacy and the rate of bacterial clearance in high-dose group (90.9%, 72.7%) were obviously higher than those in routine-dose group (62.5%, 41.7%), the hospitalization days were shorter than those in routine-dose group, the differences were significant (P 0.05). Conclusions For pneumonia caused by carbapenems-resistant acinetobacter baumannii, high-dose of tigecycline combined with cefbperazone-sulbactam is a better therapeutic method, because of the better clinical efficacy, the higher bacterial clearance rate, lower hospitalization days, and there is no significant increase in the incidence of adverse reactions. Key words: Carbapenems-resistant; Acinetobacter baumannii; Peumonia; Tigecycline; High-dose